TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) represents one of the most significant therapeutic targets in neurodegenerative disease drug development. Genetic evidence strongly links TREM2 variants to Alzheimer's disease risk, with loss-of-function mutations increasing disease susceptibility approximately 3-4 fold. This has driven substantial pharmaceutical investment in TREM2-modulating therapeutics, with over 15 clinical-stage programs and numerous preclinical candidates. The investment landscape spans multiple modalities including monoclonal antibodies, small molecules, and gene therapy approaches, with leading programs from Biogen, Regeneron, Roche, and AC Immune.
| Drug Name | Company | Modality | Indication | Phase | Status |
|-----------|---------|----------|-------------|-------|--------|
| AL002 | AC Immune / Genentech | mAb (agonist) | Alzheimer's Disease | Phase 2 | Ongoing (TRAILBLAZER-ALZ 3) |
| AL002A | AC Immune / Genentech | mAb (agonist) | Alzheimer's Disease | Phase 2 | Ongoing |
| JBH-426 | Jambru / BMS | mAb (agonist) | Alzheimer's Disease | Phase 1 | Active |
| GTX-102 | GTxomics | Peptide | Alzheimer's Disease | Phase 1 | Recruiting |
| BCT-200 | BioCentury | mAb | Alzheimer's Disease | Phase 1 | Active |
| AR-R17779 | Alector | mAb (agonist) | Alzheimer's Disease | Phase 1 | Completed |
| Company |
Modality |
Target |
Indication |
| ProMIS Neurosciences |
mAb |
TREM2 |
Alzheimer's Disease |
| Shionogi |
Small molecule |
TREM2 agonist |
Neurodegeneration |
| Denali Therapeutics |
Small molecule |
TREM2 agonist |
Alzheimer's Disease |
| Neuropore Therapies |
Small molecule |
TREM2 modulator |
Alzheimer's Disease |
TREM2 exerts its therapeutic effects through multiple interconnected mechanisms:
-
Microglial Phagocytosis Enhancement
- TREM2 activation triggers macrophage recolonization
- Enhances clearance of amyloid-beta plaques
- Promotes microglial survival and proliferation
-
Inflammatory Modulation
- Shifts microglial phenotype from DAM (Disease-Associated Microglia) to homeostatic state
- Reduces neurotoxic inflammation
- Promotes tissue repair functions
-
Metabolic Reprogramming
- Enhances microglial energy metabolism
- Supports lipid metabolism required for myelin maintenance
flowchart TD
classDef blue fill:#e1f5fe,stroke:#333,stroke-width:1px
classDef orange fill:#fff3e0,stroke:#333,stroke-width:1px
classDef green fill:#c8e6c9,stroke:#333,stroke-width:1px
classDef red fill:#ffcdd2,stroke:#333,stroke-width:1px
classDef purple fill:#f3e5f5,stroke:#333,stroke-width:1px
A["TREM2 Agonist<br/>(AL002, AL003) [^1]"]:::blue --> B["TREM2 Receptor<br/>Activation"]
B --> C["DAP12 ITAM<br/>Signaling"]
C --> D{"Syk Kinase<br/>Pathway"}
D --> E["Phagocytosis<br/>Enhancement [^2]"]
D --> F["Inflammatory<br/>Modulation"]
D --> G["Metabolic<br/>Reprogramming"]
E --> H["Amyloid<br/>Clearance"]:::green
F --> I["Reduced Neuroinflammation"]:::green
G --> J["Microglial<br/>Survival"]:::green
H --> K["Neuroprotection"]:::green
I --> K
J --> K
click A "/therapeutics/trem2-therapeutics" "TREM2 Therapeutics"
click B "/proteins/trem2" "TREM2 Protein"
click H "/diseases/alzheimer's-disease" "Alzheimer's Disease"
click E "/mechanisms/microglia-neuroinflammation" "Microglial Phagocytosis"
- Agonist Approach (Primary): Enhance TREM2 signaling to promote protective microglial functions
- Antagonist Approach (Exploratory): Block excessive TREM2 signaling in certain disease contexts
- Lead Program: AL002
- Investment: >$500M in partnership
- Strategy: First-in-class TREM2 agonist monoclonal antibody
- Clinical Status: Phase 2 ongoing (TRAILBLAZER-ALZ 3)
- Mechanism: Agonistic antibody targeting TREM2 extracellular domain
- Programs: Multiple early-stage TREM2 programs
- Strategy: Leveraging Alzheimer's disease franchise (Aduhelm, Leqembi)
- Focus: Antibody-based therapeutics
- Programs: Anti-TREM2 antibodies in development
- Advantage: Proprietary VelocImmune platform for antibody discovery
- Connection: Through Genentech partnership with AC Immune
- Resources: Global clinical trial infrastructure
- Status: Developed AL-002, partnered with AC Immune/Genentech
- Approach: Innate immune checkpoint inhibition
- Modality: Peptide-based TREM2 modulator
- Advantage: Blood-brain barrier penetration
- Phase: Phase 1 recruiting
- Approach: Novel conformation-specific antibodies
- Target: Misfolded TREM2 aggregates
- University of Washington: TREM2 biology and biomarkers
- Washington University in St. Louis: TREM2 variant research
- German Center for Neurodegenerative Diseases (DZNE): Basic TREM2 mechanisms
-
NCT05189193 - AL002 in Early Alzheimer's Disease (TRAILBLAZER-ALZ 3)
- Sponsor: AC Immune / Genentech
- Phase: Phase 2
- Enrollment: 315 participants
- Primary Outcome: Safety, tolerability, biomarkers
- Status: Ongoing (as of 2026)
- Note: Results not yet publicly available
-
NCT05858347 - JBH-426 First-in-Human Study
- Sponsor: Jambru (BMS)
- Phase: Phase 1
- Focus: Dose-escalation, safety
-
NCT05462106 - GTX-102 in Alzheimer's Disease
- Sponsor: GTxomics
- Phase: Phase 1
- Focus: Safety, PK/PD
- NCT04136834 - AL-002 First-in-Human
- Status: Completed
- Results: Safety established, biomarker signals observed
Several TREM2 programs have been discontinued due to efficacy or safety concerns:
- Early TREM2 antibodies from unknown sponsors
- Small molecule programs terminated in preclinical stages
-
Biomarker Development
- Need for validated TREM2 engagement biomarkers
- soluble TREM2 (sTREM2) as potential pharmacodynamic marker
- PET ligands for microglial activation
-
Patient Selection
- No validated companion diagnostics for TREM2-targeted therapies
- Unknown benefit of TREM2 variant status on treatment response
-
Mechanism Validation
- Unclear which downstream pathway is most therapeutically relevant
- Need for better understanding of TREM2 biology in human CNS
-
Combination Therapy
- Limited exploration of TREM2 + anti-amyloid combinations
- Unknown optimal sequencing with approved AD therapies
-
Disease indications
- Primarily focused on Alzheimer's disease
- Limited exploration in Parkinson's disease, ALS, other neurodegeneration
-
Delivery Modalities
- All current programs are injectable
- Need for oral or CNS-penetrant small molecules
-
Reimbursement Framework
- Unclear pricing models for neurodegenerative disease therapeutics
- Dependent on clinical efficacy outcomes
-
Manufacturing
- Complex antibody therapeutics require specialized manufacturing
- Limited CDMO capacity for TREM2 programs
- Clinical Risk: High failure rate in Alzheimer's disease (>99% in Phase 3)
- Competitive Risk: Multiple programs targeting similar mechanism
- Regulatory Risk: FDA/EMA scrutiny on Alzheimer's disease endpoints
- Genetic Validation: TREM2 variants provide strong genetic link to disease
- Unmet Need: No disease-modifying therapies for most neurodegenerative conditions
- Combination Potential: Synergy with existing amyloid-targeting therapies
- Addressable Population: ~6 million Alzheimer's disease patients in US, ~55 million globally
- Potential Market Size: $10-20B annually if successful
- Development Timeline: 5-8 years to potential approval
](https://www.alzforum.org/trem2)